Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

Core Insights - Genmab A/S will hold its 2025 R&D Update and ASH Data Review Meeting virtually on December 11, 2025, at 11:00 AM Eastern Time, which can be accessed via live webcast [1] - The meeting is not part of the official ASH Annual Meeting program [2] Company Overview - Genmab is an international biotechnology company focused on improving patient lives through innovative antibody therapeutics, with over 25 years of experience in developing next-generation antibody technology platforms [3] - The company aims to transform the lives of individuals with cancer and other serious diseases by 2030 through its proprietary pipeline, which includes bispecific T-cell engagers and antibody-drug conjugates [3] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [4]